Indivior (NASDAQ:INDV) Trading Down 4.2% – Time to Sell?

Indivior PLC (NASDAQ:INDV) shares traded down 4.2% during trading on Wednesday . The stock traded as low as $9.33 and last traded at $9.41. 179,048 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 373,577 shares. The stock had previously closed at $9.82.

Analyst Ratings Changes

Several research analysts have recently weighed in on INDV shares. Piper Sandler reiterated an “overweight” rating and set a $22.00 price objective on shares of Indivior in a report on Friday, September 13th. Craig Hallum cut their price target on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th.

Indivior Stock Down 3.9 %

The stock has a fifty day moving average of $11.31 and a two-hundred day moving average of $14.88. The company has a quick ratio of 0.68, a current ratio of 0.85 and a debt-to-equity ratio of 23.50. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 944.00 and a beta of 0.68.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.04. The business had revenue of $299.00 million for the quarter, compared to analyst estimates of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. As a group, analysts predict that Indivior PLC will post 1.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Indivior

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC grew its stake in shares of Indivior by 32.0% in the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock valued at $407,000 after buying an additional 6,121 shares in the last quarter. Susquehanna International Group Ltd. purchased a new position in Indivior in the 2nd quarter worth approximately $3,224,000. Millennium Management LLC grew its position in Indivior by 48.1% in the second quarter. Millennium Management LLC now owns 493,313 shares of the company’s stock valued at $7,952,000 after acquiring an additional 160,282 shares in the last quarter. Marshall Wace LLP grew its position in Indivior by 493.2% in the second quarter. Marshall Wace LLP now owns 73,732 shares of the company’s stock valued at $1,189,000 after acquiring an additional 61,302 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Indivior during the second quarter valued at approximately $249,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.